Serum oncostatin M in multiple myeloma: association with prognostic factors
| Autor: | Kari Pulkki, Tarja-Terttu Pelliniemi, Kari Koskela, Kari Remes, A. Rajamäki |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Male
medicine.medical_specialty Myeloma protein medicine.medical_treatment Enzyme-Linked Immunosorbent Assay Oncostatin M Sensitivity and Specificity hemic and lymphatic diseases Immunopathology Internal medicine medicine Tumor Cells Cultured Humans Beta (finance) Interleukin 6 Multiple myeloma Aged biology business.industry Interleukin-6 fungi Hematology Middle Aged medicine.disease Prognosis Endocrinology Cytokine C-Reactive Protein Cell culture biology.protein Female business Multiple Myeloma Peptides beta 2-Microglobulin |
| Zdroj: | British journal of haematology. 96(1) |
| ISSN: | 0007-1048 |
| Popis: | The serum concentration of oncostatin M (OSM) was measured in 40 multiple myeloma patients at diagnosis. Serum OSM level exceeded the sensitivity limit of the ELISA assay in eight (20%) of these patients (OSM+ patients). The serum levels of IL-6, another member of the gp180 cytokine family and C-reactive protein (CRP) as a surrogate of IL-6 were significantly higher in OSM+ patients. There was a trend towards higher serum beta 2M concentration in OSM+ patients, whereas there was no difference in the serum sIL-6R level or clinical data (age, gender, myeloma protein or stage) between the two groups. Two human myeloma cell lines secreted OSM and IL-6, but not IL-11 or leukaemia inhibitory factor (LIF), which suggests an important role for OSM and IL-6 in supporting growth of myeloma cells. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text